Optimized Fmoc solid-phase synthesis of Thymosin alpha1 by side-chain anchoring onto a PEG resin.
García-Ramos. Yésica Y; Giraud. Matthieu M; Tulla-Puche. Judit J; Albericio. Fernando F
Key Findings
- Thymosin‑alpha‑1 is hard to synthesize because of consecutive beta‑branched residues and many protecting groups
- A stepwise solid‑phase synthesis on a polyethylene‑glycol resin reduces complexity
- The new method enables larger‑scale production of the peptide
Practical Outcomes
- For experienced DIY chemists, this protocol offers a more straightforward route to produce thymosin‑alpha‑1 in bulk, potentially lowering cost and dependence on commercial suppliers.
Summary
Researchers created a simpler way to make the 28‑amino‑acid peptide thymosin‑alpha‑1 using a solid‑phase technique on a PEG resin, which makes the process easier to scale up.
Abstract
Thymosin alpha1 is a 28-amino acid acetylated peptide used for the treatment of hepatitis B and C. This peptide has a difficult sequence because of the presence of consecutive beta-branched amino acids and shows a tendency to form beta-sheet structures, partly as a result of the many protecting groups required to assemble the peptide (up to 20 side-chain protecting groups). Consequently, its synthesis has been generally achieved by convergent solution chemistry. Here we report a straightforward stepwise solid-phase synthesis on a polyethylene glycol solid-support that enables the scaling-up of this key therapeutic peptide.
Study Information
pubmed
2009
10.1002/bip.21317
10
37